08/18/2015

ORGENTEC Diagnostika GmbH

Acquisition of Corgenix Completed by ORGENTEC Diagnostika

US Affiliate Expands Specialty Diagnostics Company’s Global Presence and Test Menu


Mainz, March 19 2015 – ORGENTEC Diagnostika has acquired Corgenix Medical Corporation, headquartered in Broomfield, Colorado, USA. “The company gives us an immediate and important presence in the United States,” said Werner Hofacher, CEO. “The acquisition is part of a strategy to globally expand ORGENTEC’s leading position in laboratory diagnostics and diagnostics of rare diseases.”


Corgenix develops and markets specialty diagnostic test kits on the United States and worldwide. For ORGENTEC, now present in the important US market, that is an important step forward in the company’s further development. “This acquisition brings together two highly regarded innovators in the specialty diagnostics market that allows for the use of strategic synergies to develop platform concepts with a global presence.” as to Dr. Stephan Becker, COO of ORGENTEC.



About ORGENTEC and Corgenix


In-vitro diagnostic products by ORGENTEC and Corgenix comprise more than 350 laboratory tests, primarily enzyme-linked immunosorbent assays (ELISA), that contribute to the diagnosis of rheumatic diseases, thrombosis and diseases of the gastrointestinal tract as well as infectious diseases .


The product range embraces enzyme immunoassays such as ELISA assays or kits for the automatic analyzer Alegria®, immunofluorescence tests ( IFT ) and immunoblots. Furthermore, Corgenix provides metabolite tests as “AspirinWorks®” and is the world’s first provider of an FDA-approved and WHO-recognized ELISA rapid test for the detection of an Ebola infection, already at the bedside.